Halozyme Shares Up 11.6% with Momentum A Score and $6.51 EPS Forecast
In the past four weeks, Halozyme Therapeutics’ shares rose 11.6% alongside a top-tier Momentum Style Score of A and VGM Score of A, while maintaining a Zacks Rank #3 (Hold). Analysts lifted fiscal 2025 EPS estimates by $0.23 to $6.51, following a 14.1% average earnings surprise.
1. Zacks Rank and Style Scores
Halozyme Therapeutics holds a Zacks Rank #3 (Hold) and boasts top-tier Style Scores, including an A rating for both Momentum and VGM. These ratings reflect strong trend-based performance and a balanced combination of value, growth, and momentum factors.
2. Recent Share Performance
Shares of Halozyme have climbed 11.6% over the past four weeks as momentum investors respond to positive price trends and improving earnings outlooks. The Momentum Style Score of A indicates robust recent price strength compared to industry peers.
3. Analyst Estimate Revisions
Over the past 60 days, four analysts revised fiscal 2025 EPS estimates upward by a total of $0.23, bringing the consensus outlook to $6.51 per share. Halozyme has delivered an average earnings surprise of +14.1%, underscoring stronger-than-expected quarterly results.
4. ENHANZE Platform and Business Model
Based in San Diego, Halozyme develops oncology treatments and licenses its ENHANZE drug delivery technology for subcutaneous administration of partner drugs. This platform licensing model generates recurring revenue streams through royalties and upfront fees.